Egetis Therapeutics Ab · OMXSTO:EGTX
Egetis Therapeutics Ab — Investor Presentation (June 2024)
84 slides from Egetis Therapeutics Ab's investor presentation, June 2024
Slide 1: We Care for the Rare: Corporate presentation June 2024
WE CARE FOR THE RARE Corporate presentation June 2024 An integrated orphan drug company, focusing on late-stage development for commercialization ©2024 Egetis Therapeutics. All rights reserved.
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. IMPORTANT: You must read the
Slide 3: Agenda
Agenda 1. An integrated orphan drug company, focusing on late-stage development for commercialization 2. Emcitate - Overview of MCT8-deficiency - Clinical experience with Emcitate - Regulatory pathway to submissions in EU and US - Commercial opportunity 3. Aladote* - Paracetamol/Acetaminophen overdo
Slide 4: An integrated orphan drug company, focusing on late-stage development
WE CARE FOR THE RARE 1. An integrated orphan drug company, focusing on late-stage development for commercialization
Slide 5: Orphan drug segment – a highly attractive opportunity
Orphan drug segment – a highly attractive opportunity Shorter clinical development time1 Higher attainable prices2 Orphan drugs attractive returns5 Phase II to launch Average # of years Mean cost per patient and year (USDk) 143,4 152,2 150,9 128,1 134,5 ORPHAN 3.8 years 1.7x 10,3% 31,2 32,4 33,7 NON
Slide 6: An integrated orphan drug company, focusing on late-stage development for commercialization
An integrated orphan drug company, focusing on late-stage development for commercialization Dedicated orphan drug company 1 Two late-stage assets: Emcitate and Aladote* 2 Emcitate MAA filed in October 2023 Pivotal trial for Emcitate NDA is ongoing 3 Highly attractive orphan drug segment Plan to laun
Slide 7: Building a sustainable orphan drug company
Building a sustainable orphan drug company • Successfully develop Emcitate for EU & US approvals in 2024/25 and Aladote post 2026 • Commercialize Emcitate and Aladote through an inhouse organization in Europe/ North America and partnerships in RoW • Realize the full potential of our products via lif
Slide 8: Egetis has delivered transformative milestones during the last 12 months
Egetis has delivered transformative milestones during the last 12 months Jul 24 Oct 9 Oct 10 Nov 10 Nov 30 First patient Submitted Secured long-term License agreement EUR 10m draw recruited in application for financing of SEK 462m, with Fujimoto for down of debt ReTRIACt study, regulatory approval a
Slide 9: Submission of application for regulatory approval in EU (MAA) for Emcitate
Submission of application for regulatory approval in PRESS EU (MAA) for Emcitate for treatment of MCT8 deficiency PRESS © 2024 Egetis Therapeutics. All rights reserved. 9
Slide 10: Egetis secured long-term financing of SEK 462m and added top-tier US specialist investor
Egetis secured long-term financing of SEK 462m and added top-tier US specialist investor as largest shareholder Announcement published on October 10, 2023 • Unique combined long-term financing, comprising SEK 172m private placement at a premium and SEK 290m debt financing ‒ First in its class in a S
Slide 11: License agreement with Fujimoto for Emcitate in Japan
Advancing rest of world with license agreement with Fujimoto for Emcitate in Japan • Highly suitable partner in Fujimoto PRESS ‒ Private company in Osaka, Japan, founded in 1933 ‒ Significant experience from successfully registering and launching medicines for Blood, Neurological and Orphan diseases
Slide 12: Pipeline overview
Pipeline overview Emcitate MAA filed in October 2023 Candidate Preclinical Phase I Phase II/III MAA/NDA Comments Emcitate EU MCT8 deficiency Filed FiledOct Oct2023 2023 - Submission validated by EMA Oct 26, 2023 Emcitate US ReTRIACt MCT8 deficiency - Pivotal, 16 patients, 30-day randomized trial - T
Slide 13: Two highly promising orphan drug candidates
Two highly promising orphan drug candidates Aladote® – To prevent acute liver injury caused by Emcitate® – Therapy for MCT8 deficiency paracetamol poisoning* • MCT8 deficiency affects ~1:70,000 males: high unmet medical need, no • Paracetamol poisoning is one of the most common overdoses with availa
Slide 14: Overview of MCT8 deficiency
2. Overview of MCT8 deficiency 14
Slide 15: MCT8 deficient patients
MCT8 deficiency results in dysfunctional thyroid hormone trafficking MCT8 deficiency has two co-manifestations MCT8 deficiency results in simultaneous too high and too low New Research Sheds Light on Thyroid Hormone Transport thyroid hormone levels – causing system wide issues • In 2003, MCT8 was id
Slide 16: MCT8 deficiency: a detrimental condition with significant unmet medical need
MCT8 deficiency: a detrimental condition with significant unmet medical need What is MCT8 deficiency? What does it mean? What are the challenges? How do you manage the Quick facts from natural history2 disease? • Genetic X-linked disorder ● Non-functional MCT8 protein: ● Patients appear normal at bi
Slide 17: Natural history study revealed poor survival with a high prevalence of treatable risk factors
Natural history study revealed poor survival with a high prevalence of treatable underlying risk factors An international, retrospective, multicentre cohort study from 2014-2020 in 151 patients • 151 patients were enrolled with 73 different MCT8 (SLC16A2) mutations • Median age at diagnosis was 24.0
Slide 18: Multiple sources lead to consistent MCT8 deficiency incidence estimates
Multiple sources lead to consistent MCT8 deficiency incidence estimates Available Data Leads to Consistent Supporting our Relevant Sources & Data MCT8 Deficiency Incidence Estimates Conservative Estimate • Multiple cohorts of patients with X- linked mental retardation under study Visser et al., Clin
Slide 19: Clinical experience with Emcitate
2. Clinical experience with Emcitate 19
Slide 20: Orphan drug candidate with clear scientific and mechanistic rationale
Orphan drug candidate with clear scientific and mechanistic rationale and established safety profile Difference normal MCT8 and deficiency of MCT8 Emcitate (tiratricol) – Addressing MCT8 deficiency • Thyroid hormone T3 requires transporters such as MCT8 • Tiratricol is a small molecule thyroid hormo
Slide 21: Emcitate Overview
Emcitate® Overview Lead candidate for addressing MCT8 deficiency, a condition with high unmet medical need and no available treatment • Triac Trial I completed with significant and clinically relevant effects • Erasmus Medical Center cohort study confirms long-term efficacy and safety for up to 6 ye
Slide 22: Overview of completed Phase IIb – Triac Trial I
Overview of completed Phase IIb – Triac Trial I • Evaluate the efficacy and safety of oral administration of tiratricol in male patients with MCT8 deficiency of all ages Primary objective and • Highly significant primary outcome - Change in T3 serum concentrations results • Safe and tolerable • Resu
Slide 23: Consistent, clinically relevant and highly significant results
Consistent, clinically relevant and highly significant results Triac Trial I: Reached target level serum T3 & improvements in clinically relevant outcome measures 10 T0 (Baseline) 8 T12 (12 month) p < 0.0001 Serum T3 (nmol/l) 6 4 2 Normal range 0 Endpoints Baseline mean (± SD) 12 months mean (± SD)
Slide 24: Triac Trial I: Indication of positive effect on neurocognitive development
Triac Trial I: Indication of positive effect on neurocognitive development In the youngest patients which is further studied in ongoing, fully recruited, Triac Trial II 40 T0 (Baseline) T12 (12 months) 30 GMFM score (%)1) 20 10 0 # # # Patients 1.5 to <4 years 4 to <10 years ≥10 years Age at baselin
Slide 25: Long-term efficacy and safety of Emcitate in MCT8 deficiency patients
Long-term efficacy and safety of Emcitate® in MCT8 deficiency patients Published in October, 2021 • Investigator-initiated real-world cohort study at 33 sites conducted by the Erasmus Medical Center • Investigated efficacy and safety of Emcitate in 67 patients with MCT8 deficiency ‒ Median baseline
Slide 26: New patient cohort of equal size to the Triac Trial I
New patient cohort of equal size to the Triac Trial I Long term follow up, up to >6 years Triac Trial I N=46 Triac Trial I patients New patients Available for long-term From managed access program monitoring N=40 N=27 EMC cohort Published in JCEM N=67 26 © 2024 Egetis Therapeutics. All rights reserv
Slide 27: New cohort confirms primary endpoint results in Triac Trial I
New cohort confirms primary endpoint results in Triac Trial I Fast and durable normalization of T3 values in almost all patients p<0.0001 27 © 2024 Egetis Therapeutics. All rights reserved.
Slide 28: Consistent, clinically relevant and highly significant results across endpoints
Consistent, clinically relevant and highly significant results across endpoints • Data confirm the positive results from previous study, Triac Trial I • Normalization of serum T3 corresponds to improvement in thyroid hormone status in end target tissues • Beneficial effects are maintained or continu
Slide 29: Emcitate - regulatory pathway to submissions in EU and US
2. Emcitate® - regulatory pathway to submissions in EU and US 2024 Egetis Therapeutics. All rights reserved. 29
Slide 30: Regulatory features of Emcitate for MCT8 deficiency
Regulatory features of Emcitate for MCT8 deficiency Orphan drug designation for MCT8 deficiency ODD Eligibility: Market exclusivity 10y (EU) & 7y (US) Fast Fast track designation (FDA) track Eligibility: Six months review of NDA & rolling submission Rare pediatric disease designation (FDA) PRV Eligi
Slide 31: Emcitate regulatory pathway in EU and US
4. Emcitate regulatory pathway in EU and US The first potential treatment for MCT8 deficiency, an ultra rare genetic disease with high unmet medical need and no available treatment Included in MAA in EU submitted on October 9, 2023 Complementary to MAA & NDA To be included in NDA in US with Fast Tra
Slide 32: ReTRIACt: withdrawal of Emcitate in males with MCT8 Deficiency
ReTRIACt: withdrawal of Emcitate in males with MCT8 Deficiency Pivotal randomized placebo-controlled trial for NDA submission • Proportion of participants who meet the rescue criterion (serum total T3 > ULN) Primary during the 30-day double-blind Randomized Treatment Period endpoint • Change in card
Slide 33: Design of the ReTRIACt clinical trial
Design of the ReTRIACt clinical trial Requested by the FDA as pivotal for the New Drug Application in the USA • A 30-day, randomized placebo-controlled withdrawal study in 16 patients Primary endpoint Patients already on therapy n=8 • Design agreed with FDA tiratricol tiratricol tiratricol • The stu
Slide 34: Current status of ReTRIACt trial (as of May 3, 2024)
Current status of ReTRIACt trial (as of May 3, 2024) Map not to scale > 20 Eligible Addenbrooke’s Hospital CHOP Cambridge, UK patients Philadelphia Erasmus Medical Center Rotterdam, NL identified and remaining for Saint Louis University recruitment going forward New sites to start recruitment • 13 p
Slide 35: Triac Trial II objective and design
Triac Trial II objective and design: Triac Trial II was designed to investigate a potential additional benefit on neurocognitive development in 22 patients with MCT8 deficiency below 30 months of age treated with Emcitate® (tiratricol) during 96 weeks • Confirm findings from Triac Trial I in younges
Slide 36: Pipeline milestones
Pipeline milestones • Topline results ReTRIACt for US NDA • Filing US NDA under Fast Track Designation ✓ Results Triac Trial II, June 19, 2024 ✓ US & EU ODD RTH-b ✓ FPI ReTRIACt for US NDA • EU approval and launch Emcitate® ✓ Recruitment completed in ✓ Filing EU MAA Oct 9, ‘23 • US approval and laun
Slide 37: FDA granted Rare Pediatric Disease designation to Emcitate
FDA granted Rare Pediatric Disease designation to Emcitate® US Rare Pediatric Disease Priority Review Voucher (PRV) provides a ~$100m opportunity Overview of PRV Examples of PRVs sold Seller Buyer Value Year • The FDA grants Rare Pediatric Disease designation (RPD) to therapies for serious or life-t
Slide 38: Emcitate - Commercial opportunity
2. Emcitate® - Commercial opportunity 38
Slide 39: Emcitate – alleviating patient and societal burden
Emcitate®– alleviating patient and societal burden Aiming to provide value for both patients and society MCT8 deficiency is a detrimental condition with significant unmet medical need and no approved therapy • Median life-expectancy of MCT8 patients is 35 years1 Patients • Patients underweight for a
Slide 40: Emcitate supplied globally in managed access programs
Emcitate supplied globally in managed access programs Managed access programs confirm the significant unmet medical need in MCT8 deficiency and the view on how Emcitate address it • Managed access programs MEDICINES AGENCY ‒ mechanisms to allow early access to a medicine prior to regulatory marketin
Slide 41: Commercialization possible with lean & agile team
Commercialization possible with lean & agile team Unique setting for Emcitate in MCT8 deficiency Seizing opportunity for cost-effective value creation Addressing unmet medical need • Targeted stakeholder interactions • Efficiency gains through global-country team coordination No competition External
Slide 42: Egetis commercialization of Emcitate
Egetis commercialization of Emcitate Retaining most value by managing the US & European launches through the Egetis team To optimize the launch, we will focus our own resources on US and Europe (> 70% of sales for most ultra-orphans) Stepwise establishing Egetis commercial capabilities • Preparing f
Slide 43: Building commercial organization to execute on key activities for launch
Building commercial organization to execute on key activities at the right time for launch success Key projects driven by recognized industry talents recruited to the Egetis Commercial & Medical Affairs Team – Leadership team brings launch skills and best practices from in total 100+ years at intern
Slide 44: Focusing on Critical Areas for Launch Success
Focusing on Critical Areas for Launch Success Aiming to Improve the Lives of MCT8 Deficiency Patients and their Caregivers IDENTIFY PATIENTS ENSURE ACCESS Boost disease awareness, educate on Preparing for broad access to Emcitate as disease*, diagnosis and newborn soon as possible after marketing sc
Slide 45: Enabling patient identification through disease awareness
Enabling patient identification through disease awareness Increasing number of previously un- / misdiagnosed and treatment naïve patients are being identified mct8deficiency.com EXHIBIT AT DISEASE AWARENESS COLLABORATION WITH OPTIMUM CHANNEL MIX SCIENTIFIC/MEDICAL AND EDUCATION PAGs & KOLs FOR MAXIM
Slide 46: Aiming for broad access at optimal reimbursed price
Aiming for broad access at optimal reimbursed price Everyone who can benefit from LAUNCH treatment, gets access to reimbursed VISION Emcitate asap after regulatory approval Fast and accurate CRITICAL SUCCESS Payer support for reimbursement diagnosis of FACTORS at optimal price affected patients Unde
Slide 47: Developing a compelling Emcitate clinical and economic value proposition
Developing a compelling Emcitate clinical and economic value proposition to secure reimbursement & access Key for payer assessments to describe unmet need & quantify burden of disease • A significant unmet medical need, addressed by the Emcitate clinical development program • In addition, generating
Slide 48: Our Expanded Access Program is a vital step on our path to commercialization
Our Expanded Access Program is a vital step on our path to commercialization Tiratricol (Emcitate) Expanded Access Program sites A significant asset to both the patients and Egetis launch readiness • Provided early and sustainable access to therapy • Expose physicians to Emcitate prior to commercial
Slide 49: Preparing for broad access at an optimized price
Preparing for broad access at an optimized price Analogue selection criteria ✓ Rarity (ultra-orphan) ✓ Life-long treatment Most MCT8 deficiency patients will be eligible for ✓ Paediatric ✓ Life threatening, debilitating government insurance ✓ No treatment options • Predominantly government payer mix
Slide 50: Paracetamol/Acetaminophen overdose and clinical experience with Aladote
3. Paracetamol/Acetaminophen overdose and clinical experience with Aladote * In-house development of Aladote has been parked until Emcitate MCT8 deficiency submissions have been completed 50
Slide 51: Paracetamol/acetaminophen poisoning
Paracetamol/acetaminophen poisoning – no adequate treatment for increased-risk patients What is • Minimum toxic dose of paracetamol/acetaminophen in adults is only 7.5g paracetamol/ acetaminophen • Risk factors include malnutrition, alcoholism and consumption of other medications poisoning? • Parace
Slide 52: Orphan drug candidate with clear scientific and mechanistic rationale
Orphan drug candidate with clear scientific and mechanistic rationale Early presenters (<8h) Late presenters (>8h) are at increased-risk for liver injury NAC treatment effective against liver injury NAC treatment + Aladote® to prevent liver injury • Liver glutathione (GSH) replenished by NAC, toxic
Slide 53: Overview of completed Phase Ib/IIa
Overview of completed Phase Ib/IIa • Met primary endpoint of safety tolerability in the combination of Aladote® and NAC Primary • Results presented at the 58th Annual Meeting of the Society of Toxicology, EASL objective and ILC in April, Vienna and published in Lancet’s journal EBioMedicine in 2019
Slide 54: Positive proof-of-principle Phase Ib/IIa results
Positive proof-of-principle Phase Ib/IIa results Indicates that Aladote may reduce liver injury Safety & tolerability Liver injury – ALT1 pre-defined secondary outcome NAC + 2 NAC + 5 NAC + 10 NAC + 2 NAC + 5 NAC + 10 % of patients needing mol/kg mol/kg mol/kg mol/kg mol/kg mol/kg additional N
Slide 55: Aladote demonstrates consistent results of reduced liver injury
Aladote® demonstrates consistent results of reduced liver injury as measured by exploratory biomarkers K18K18 ccK18 ccK18 miR-122 miR-122 10 10 10 Relative change from baseline Relative change from baseline Relative change from baseline NAC alone NAC alone NAC alone NAC and 2umol/kg NAC and 2umol/kg
Slide 56: Aladote - Regulatory pathway to submissions in EU and US
3. Aladote® - Regulatory pathway to submissions in EU and US* * In-house development of Aladote has been parked until Emcitate MCT8 deficiency submissions have been completed 2024 Egetis Therapeutics. All rights reserved. 56
Slide 57: ALBATROSS: Phase IIb/III study for US/EU regulatory submission
ALBATROSS: Phase IIb/III study for US/EU regulatory submission* • Patients who have overdosed on paracetamol with increased Patient risk of liver damage due to late arrival at hospital (> 8h) who population need treatment with NAC NAC regimen • Approved 21 hours NAC regimen Treatment • 4 groups in c
Slide 58: ALBATROSS: Aladote Phase IIb/III study design
ALBATROSS: Aladote Phase IIb/III study design Seamless Phase IIb/III design Based on the acetaminophen/paracetamol levels eligible patients will be randomised in a 1:1:1:1 ratio to one of the 4 treatment arms in combination with NAC: 35 35 55 140 pts interim 250 pts 35 analysis 55 35 • Stop the stud
Slide 59: Aladote clinical development timelines
Aladote clinical development timelines Orphan Drug Designation EU • Interim analysis CTA pivotal • Recruitment completed Phase IIb/III study and topline results 2022 tbc tbc tbc • Start pivotal Phase • Regulatory submissions IIb/III study (after Europe/US Emcitate submissions have been completed) •
Slide 60: Aladote - Commercial opportunity
3. Aladote® - Commercial opportunity 2024 Egetis Therapeutics. All rights reserved. 60
Slide 61: Aladote – alleviating patient and societal burden
Aladote– alleviating patient and societal burden Aiming to provide value for both patients and society POD is a life threatening condition with remaining medical needs • POD (paracetamol/acetaminophen overdose) can lead to acute liver failure, liver transplant or death Patients • In US and UK togeth
Slide 62: Commercialisation of Aladote for high-risk POD patients
Commercialisation of Aladote for high-risk POD patients Very cost-effective since possible to launch through members of Emcitate team Favorable conditions for launch success Addressing life-threatening condition • Anologue antidotes priced at $3.5k – 50k Addressing unmet medical need • National emer
Slide 63: Analogue antidotes priced at $3.5k – 50k
Analogue antidotes priced at $ 3.5k – 50k National emergency hospital stocking guidelines - opportunity for rapid market penetration • Various antidotes, e.g. vs. drug overdosing, metal poisoning, snake bites and reversal of anticoagulant treatment effects • Limit morbidity/mortality when used withi
Slide 64: The attractiveness of the orphan drug segment
4. The attractiveness of the orphan drug segment 2024 Egetis Therapeutics. All rights reserved. 64
Slide 65: Orphan drug segment – a highly attractive opportunity
Orphan drug segment – a highly attractive opportunity Orphan drug designation is awarded to • Less extensive clinical trials 1 products targeting limited disease populations1 Development • Agile and faster development process • Lower costs • Lower development risk 2 More than 7,000 known rare diseas
Slide 66: CAGR estimates of total pharmaceutical market vs orphan
CAGR estimates of total pharmaceutical market vs orphan The global orphan or rare disease market size was valued at an estimated USD 140 – 150 bn and is expected to grow at 10-14% CAGR over the coming five years. Source: EvaluatePharma, Pareto. 2024 Egetis Therapeutics. All rights reserved. 66
Slide 67: Summary
5. Summary 2024 Egetis Therapeutics. All rights reserved. 2024-01-25 67
Slide 68: Commercialisation of Emcitate & Aladote
Commercialisation of Emcitate & Aladote Commercial infrastructure build up initiated Strong success factors… …for sustainable, profitable & lean commercialisation 1 High unmet medical need without competing compounds • Building inhouse commercial capabilities for launch of Emcitate® and Aladote® in
Slide 69: Egetis – a de-risked biotech with substantial unlocked potential
Egetis – a de-risked biotech with substantial unlocked potential • Late stage biotech “under the radar”, developing the first therapy for a devastating genetic disorder ‒ Strong team with established track record in the orphan drug space, including SOBI, Alexion, Biomarin, Biogen, Vertex, Sarepta, S
Slide 70: Two highly promising orphan drug candidates
Two highly promising orphan drug candidates Aladote® – To prevent acute liver injury caused by Emcitate® – Therapy for MCT8 deficiency paracetamol poisoning* • MCT8 deficiency affects ~1:70,000 males: high unmet medical need, no • Paracetamol poisoning is one of the most common overdoses with availa
Slide 71: Pipeline milestones
Pipeline milestones • Topline results ReTRIACt for US NDA • Filing US NDA under Fast Track Designation ✓ Results Triac Trial II, June 19, 2024 ✓ US & EU ODD RTH-b ✓ FPI ReTRIACt for US NDA • EU approval and launch Emcitate® ✓ Recruitment completed in ✓ Filing EU MAA Oct 9, ‘23 • US approval and laun
Slide 72: An integrated orphan drug company, focusing on late-stage development for commercialization
An integrated orphan drug company, focusing on late-stage development for commercialization Dedicated orphan drug company 1 Two late-stage assets: Emcitate and Aladote* 2 Emcitate MAA filed in October 2023 Pivotal trial for Emcitate NDA is ongoing 3 Highly attractive orphan drug segment Plan to laun
Slide 73: Appendix
A. Appendix 2024 Egetis Therapeutics. All rights reserved. 2024-01-25 73
Slide 74: Roadmap to site initiations in the ReTRIACt trial
Roadmap to site initiations in the ReTRIACt trial Regulatory feedback Revision to study documentation -> Substantial amendment Develop detailed Agree on clinical trial CTA application/ Ethical review by clinical study Patient design with regulatory Regulatory review IRB/IEC Site initiation protocol
Slide 75: Termination of discussions regarding a potential acquisition of the Company
Termination of discussions regarding a potential acquisition of the Company Announcement published on May 23, 2023 • Discussions, triggered by an unsolicited approach by an external party, have taken place between certain external parties and Egetis regarding a potential acquisition of the Company •
Slide 76: Discovery of Emcitate (Triac, tiratricol)
Discovery of Emcitate (Triac, tiratricol) T3 Triac (tiratricol) 2024 Egetis Therapeutics. All rights reserved. 2024-01-25 76
Slide 77: Resistance to Thyroid Hormone type Beta (RTH-β)
Resistance to Thyroid Hormone type Beta (RTH-β) Potential indication expansion for Emcitate into non-overlapping patient population Characteristics of RTH-β Emcitate as potential treatment for RTH-β • Caused by mutations in thyroid hormone receptor • Emcitate efficacious in restoring signaling in ma
Slide 78: Leadership team with global experience & proven track record
Leadership team with global experience & proven track record Nicklas Westerholm Desiree Luthman Katayoun Welin-Berger, PhD CEO VP Regulatory Affairs VP Technical Operations • Joined 2017 • Joined 2023 • Joined 2023 • AstraZeneca 1995-2017 • Global regulatory professional, >25y experience • VP Operat
Slide 79: Board of directors
Board of directors Mats Blom Thomas Lönngren Chair of the board since 2024 Chair of the board since 2021 • Shares in Egetis: 3,134,762 • Shares in Egetis: 283,158 • BA, Business Administration & Economics, Lund University; • MSc in social and regulatory pharmacy and a degree in MBA, IESE University
Slide 80: Share Register, Cash and Market Cap
Share Register, Cash and Market Cap • Cash position Dec 31, 2023: SEK 303M (~EUR 27M)* • Private placement Oct 10, 2023: SEK 161M (net) (~EUR 13.6M) • Debt draw down Nov 30, 2023: ~SEK 118M (EUR 10.0M) • Number of outstanding shares: 292.6M • MCap: ~SEK 2.0 billion** • Listing venue: Nasdaq Stockhol
Slide 81: Acquisition of Rare Thyroid Therapeutics on November 5, 2020
Acquisition of Rare Thyroid Therapeutics on November 5, 2020
Slide 82: The combination will drive synergies
The combination will drive synergies PledPharma and Rare Thyroid Therapeutics merged to launch a new company + = PledPharma Rare Thyroid Therapeutics Synergistic orphan drug focus • Team with profound late-stage drug • Team with strong track-record of identifying • 2020 accelerated PledPharma’s stra
Slide 83: The acquisition and rights issue
The acquisition and rights issue Institutional investor base broadened Acquisition Rights issue On 5 November 2020, PledPharma Successfully raised SEK 250 million in oversubscribed rights issue acquired all outstanding common shares (c. SEK 200m) and utilized overallotment option (c. SEK 50m) in Rar
Slide 84: Thank you!
Thank you! Egetis Therapeutics egetis.com karl.hard@egetis.com 2024 Egetis Therapeutics. All rights reserved. 2024-01-25 84
Egetis Therapeutics — Investor Presentation (June 2024) on 6ix